Chuck Triano | SVP, IR |
Albert Bourla | CEO |
Frank D'Amelio | CFO |
Mikael Dolsten | President of Worldwide Research and Development |
Angela Hwang | Group President, Pfizer Biopharmaceuticals Group |
John Young | Chief Commercial Officer |
Doug Lankler | General Counsel |
Tim Anderson | Wolfe Research |
Vamil Divan | Credit Suisse |
Chris Schott | J.P. Morgan |
Geoff Meacham | Barclays Capital |
Andrew Baum | Citi |
Umer Raffat | Evercore ISI |
Louise Chen | Cantor Fitzgerald |
Jason Gerberry | Bank of America Merrill Lynch |
Alex Arfaei | BMO Capital Markets |
Navin Jacob | UBS |
Seamus Fernandez | Guggenheim Securities |
David Risinger | Morgan Stanley |
Kathy Miner | Cowen & Company |
Good day everyone, and welcome to Pfizer's First Quarter 2019 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead sir.